Related Experiment Video
Updated: May 2, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Unanswered questions in the management of stage I-III Merkel cell carcinoma
Jonathan S Zager1, Jane L Messina, L Frank Glass
1From the aDepartment of Cutaneous Oncology, H. Lee Moffitt Cancer Center; bDepartment of Oncologic Sciences, University of South Florida Morsani College of Medicine; and cDepartment of Anatomic Pathology, H. Lee Moffitt Cancer Center, Tampa, Florida.
Abstract:
Many unanswered questions remain about what constitutes appropriate guidelines for treatment of Merkel cell carcinoma (MCC). In this review, we address current uncertainty surrounding optimal management of MCC. These areas of uncertainty include early recognition features; clinical and histopathologic prognostic factors; optimum margins of excision of the primary tumor; indications for and value of surgical staging of the clinically negative regional nodes; optimum management of the patient with pathologically positive regional nodes; and indications for and value of radiation to the primary and regional nodes. Through identifying and elaborating on these areas of uncertainty, the authors hope to foster additional research and ultimately improve the evidence base for future iterations of the NCCN Clinical Practice Guidelines in Oncology in this rare but increasingly encountered cutaneous malignancy. The intent, however, is not to exhaustively identify all areas of controversy, but rather to highlight clinically relevant questions that further studies could address to improve the standard of care for MCC.

